A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Triple-Negative Breast Cancer (TNBC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
Contact: Study coordinator (Binghe Xu) · xubinghe@medmail.com.cn · +86-10-87788826

Study leads

Binghe Xu
Principal Investigator
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Breast Cancer · Triple Negative Breast Cancer · PD-L1 Negative

Abroad (travel likely)RecruitingPHASE2

Stamford, United States · Miami, United States

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Triple-negative Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

JS207 Combination Therapy in Triple-negative Breast Cancer

Triple-negative Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Hefei, China · Beijing, China

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Advanced Breast Cancer · Metastatic Breast Cancer · Triple Negative Breast Cancer (TNBC)

Abroad (travel likely)RecruitingPHASE2

Shanghai, China